Table 5

Antiarrhythmic medications during follow-up

Time pointTotal cohort (n = 66a)PULSE3 (n = 16)
Baseline
 None0 (0)0 (0)
 Class I or III54 (82)14 (88)
Day 90
 None18 (27)4 (25)
 Class I or III20 (30)6 (38)
Day 365
 None27 (41)5 (31)
 Class I or III9 (14)2 (13)
Time pointTotal cohort (n = 66a)PULSE3 (n = 16)
Baseline
 None0 (0)0 (0)
 Class I or III54 (82)14 (88)
Day 90
 None18 (27)4 (25)
 Class I or III20 (30)6 (38)
Day 365
 None27 (41)5 (31)
 Class I or III9 (14)2 (13)

Values are reported as incidence number (percentage). No statistical differences observed in AAD utilization between PULSE3 and PULSE1/PULSE2 cohorts.

aPaired analysis. Only subjects with 12-month follow-up included (66 of 85 subjects through 12 months).

Table 5

Antiarrhythmic medications during follow-up

Time pointTotal cohort (n = 66a)PULSE3 (n = 16)
Baseline
 None0 (0)0 (0)
 Class I or III54 (82)14 (88)
Day 90
 None18 (27)4 (25)
 Class I or III20 (30)6 (38)
Day 365
 None27 (41)5 (31)
 Class I or III9 (14)2 (13)
Time pointTotal cohort (n = 66a)PULSE3 (n = 16)
Baseline
 None0 (0)0 (0)
 Class I or III54 (82)14 (88)
Day 90
 None18 (27)4 (25)
 Class I or III20 (30)6 (38)
Day 365
 None27 (41)5 (31)
 Class I or III9 (14)2 (13)

Values are reported as incidence number (percentage). No statistical differences observed in AAD utilization between PULSE3 and PULSE1/PULSE2 cohorts.

aPaired analysis. Only subjects with 12-month follow-up included (66 of 85 subjects through 12 months).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close